Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Waldenstrom Macroglobulinemia 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Glioma 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Rituximab 24Cyclophosphamide 10fludarabine phosphate 8Bortezomib 7Lenalidomide 6Tacrolimus 5Mycophenolic Acid 5idelalisib 4ibrutinib 4Peripheral Blood Stem Cell Transplantation 4Antilymphocyte Serum 4tanespimycin 3Whole-Body Irradiation 3Radiotherapy 3Indium 3Dasatinib 3Cyclosporine 3pomalidomide 2ofatumumab 2nelarabine 2ibritumomab tiuxetan 2Vincristine 2Sirolimus 2Radiation 2Prednisone 2Polymerase Chain Reaction 2Methotrexate 2Melphalan 2Magnetic Resonance Spectroscopy 2Ipilimumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Waldenstrom Macroglobulinemia × Antibodies, Monoclonal × Clear all
NCT00265928 2008-01-28

Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

National Cancer Institute (NCI)

Phase 2 Terminated
46 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡